CJC-1295 vs GLP-1 (7-37)

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) form binds to albumin in the bloodstream, extending its half-life to several days and enabling sustained elevation of GH and IGF-1 levels. It is commonly researched alongside GHRP peptides for body composition and recovery outcomes.

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

The active endogenous form of glucagon-like peptide-1, an incretin hormone released from intestinal L-cells after eating. The mechanistic basis for the GLP-1 receptor agonist drug class (semaglutide, liraglutide). Studied for glucose regulation and appetite suppression.